#United States #New York #Kessler Topaz #Securities Fraud #Zoetis Inc

Zoetis Inc. (ZTS) Investors: A Call to Action for Class Action Lawsuit

In a significant development for investors of Zoetis Inc. (NYSE: ZTS), Kessler Topaz Meltzer & Check, LLP, a nationally recognized firm specializing in securities litigation, has announced the opportunity for affected investors to lead a class action lawsuit stemming from allegations of securities fraud. This lawsuit seeks to address potential misrepresentations made by the company regarding its operations and product adoption during a specific class period.

Important Details of the Lawsuit

The class period for this lawsuit is defined as January 14, 2025, to May 6, 2026. Investors who purchased or acquired Zoetis securities within this timeframe may qualify to be part of the legal action. The primary allegations center around materially false statements and omissions related to Zoetis's business performance, specifically regarding its market share and financial outlook.

The firm has filed the lawsuit in the Southern District of New York, noted as City of Ann Arbor Retiree Health Care Benefit Plan Trust v. Zoetis Inc., No. 26-cv-04401 (S.D.N.Y.). Investors interested in becoming lead plaintiffs must take action by July 27, 2026. This deadline is critical for those seeking a voice in the direction of the lawsuit and the potential recovery options.

Allegations Faced by Zoetis

The allegations claim that throughout the designated class period, the company made misleading statements regarding its product offerings. Notably, the complaint points out issues with:

1. Librela: A pain relief treatment for dogs, which reportedly faced declining prescription growth due to FDA warnings regarding serious potential side effects.
2. Simparica Trio: A preventive treatment for fleas and ticks that has been losing market share to cheaper competitors, raising questions about the company’s competitive position.
3. Dermatological Products: Including Apoquel and Cytopoint, which also exhibited decreased market share against rivals, further impacting Zoetis's growth narrative.

The outcomes described raised serious concerns about the validity of the company’s previous claims concerning its business health and stability.

Impact on Stock Performance

The lawsuit's announcements come on the heels of disappointing financial results for the first quarter of 2026, where Zoetis reported a significant drop in revenues from its Companion Animal business segment. Following this announcement, the stock price experienced a steep decline of 21.5% on May 7, 2026. This market reaction highlights the immediate effect that perceived financial instability and miscommunication can have on investor confidence and stock value.

Next Steps for Affected Investors

Investors who believe they have been negatively impacted by these developments are urged to consider various avenues:

• - File for Lead Plaintiff Status: Interested parties must do so by the stipulated deadline of July 27, 2026. Acting as a lead plaintiff gives investors the opportunity to represent the broader class and guide the litigation process.
• - Contact Kessler Topaz Meltzer & Check, LLP for a complimentary assessment of their case and options available for pursuing recovery. This avenue ensures that any potential actions undertaken are with legal representation and the necessary expertise.
• - Choose Legal Counsel: Investors may independently seek legal advice or chose to remain uninvolved in the litigation process, which will not impact their eligibility for any potential recovery.

About Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP (KTMC) is recognized as a leading U.S. plaintiff-side law firm, particularly noted for focusing on securities fraud and investor protection. With a remarkable track record of securing over $25 billion in recovery for affected investors, KTMC has built a reputation for excellence within the legal community. Their expertise spans various legal areas, making them a formidable resource for investors navigating complex securities litigation.

For more information about your legal rights or to discuss potential participation in this class action lawsuit, investors are encouraged to reach out to attorney Jonathan Naji at (484) 270-1453 or via email at [email protected] without any cost obligations to evaluate their options.

In conclusion, this class action suit may represent a critical opportunity for investors who have faced losses related to Zoetis Inc.'s stock performance, prompting them to seek justice and potential financial recompense through legal channels.